Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
ValueSpectrum,
- On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA…